A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

Also called NCT06220773

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 276 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06220773
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Indonesia, South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06220773. Randomized; double masking; primary purpose treatment. Start 2024-05-21 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Condition
Essential Hypertension
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
BR1019A
Intervention (Drug)
BR1019B
Intervention (Drug)
BR1019C
Intervention (Drug)
BR1019A-1
Intervention (Drug)
BR1019B-1
Intervention (Drug)
BR1019C-1
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct06220773
Content hash
eaa8a0fcd3b2f264e20d9f5473ace14aef3a4fb54c8d9fe709445d81995f2e8d